Latest Pharma and Biotech News
Biotechnology
20 May 2025 US pharma major Pfizer is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a licensing deal worth up to $6 billion for a Chinese-developed drug that targets two key cancer pathways.
Today's issue
Refine Search
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of Cancer Oncology (ASCO) meeting across its expansive cancer portfolio. 21 May 2025
Biotechnology
US biotech Moderna today announced that in consultation with the US Food and Drug Administration (FDA), the company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. 21 May 2025
Pharmaceutical
The Dementia Discovery Fund (DDF) - managed by healthcare fund manager SV Health Investors - has announced the final closing of its second fund, DDF-2, with $269 million in commitments. 21 May 2025
Pharmaceutical
Earlier this month, the US Department of Health and Human Services (HHS) said it would require all future vaccines to undergo testing in placebo-controlled trials before being approved for use. 21 May 2025
Pharmaceutical
Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent. 21 May 2025
Pharmaceutical
Swiss reproductive and women’s health medicines specialist ReproNovo today announced the successful closing of a $65 million Series A financing round, which will be used to advance its pipeline of multiple Phase II programs. 21 May 2025
Pharmaceutical
North Carolina, USA-based vTv Therapeutics has announced that screening has been reinitiated in the company’s CATT1 Phase III trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D). 21 May 2025
Biotechnology
US biotechs Protagenic Therapeutics and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. 21 May 2025
Biotechnology
UK-based Juvenescence, a clinical stage AI-enabled biotech company, has secured a total of $76 million in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors. 21 May 2025
Pharmaceutical
UK-based PureTech Health delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. 21 May 2025
Pharmaceutical
US biotech Tourmaline Bio has reported topline data from a Phase II trial of its lead asset, pacibekitug, in people with chronic kidney disease (CKD) and elevated inflammation levels associated with cardiovascular risk. 21 May 2025
Pharmaceutical
US biotech company SparX Biopharmaceutical has signed a research agreement with Mitsubishi Tanabe Pharma America aimed at advancing a new antibody-drug conjugate (ADC) that targets a novel immune cell protein. 21 May 2025
Biotechnology
German antibody drug conjugate (ADC) specialist Tubulis announced that the first program from its 2023 licensing accord with pharma major Bristol Myers Squibb has entered clinical development, triggering a significant milestone in the ongoing collaboration to develop next generation antibody drug candidates (ADCs) for the treatment of cancer. 21 May 2025
Pharmaceutical
US healthcare giant Johnson & Johnson presented long-term findings from the 24-month open-label extension of the A DUE trial of Opsynvi (macitentan and tadalafil) in pulmonary arterial hypertension (PAH) during a late-breaking oral session at the American Thoracic Society (ATS) Conference. 21 May 2025
Biotechnology
South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running patent dispute concerning exports of its 13-valent pneumococcal conjugate vaccine, SKYPneumo (pneumococcal 13-valent conjugate vaccine). 21 May 2025
Biotechnology
A panel of experts convened by the US regulator has given a cautious nod to Johnson & Johnson’s Darzalex Faspro (daratumumab/hyaluronidase-fihj) for some multiple myeloma patients. 21 May 2025
Pharmaceutical
A week after US President Donald Trump signed an executive order to bring back the Most Favored Nation (MFN) idea he introduced at the end of his first term, the US Department of Health and Human Services (HHS announced it is proceeding with implementing the order on prescription drug pricing. 20 May 2025
Pharmaceutical
German drugmaker Grünenthal has named Maren Thurow as its new vice president and head of global communications, stepping into the role at a time of significant business expansion and leadership change. She succeeds Florian Dieckmann, who had led the company’s communications function since 2021. 20 May 2025
Pharmaceutical
Australia’s digital health sector is poised for steady expansion, with the market forecast to grow at a compound annual growth rate of around 8% through 2034, according to research from data and analytics group GlobalData. 20 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
All news
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of Cancer Oncology (ASCO) meeting across its expansive cancer portfolio. 21 May 2025
Biotechnology
US biotech Moderna today announced that in consultation with the US Food and Drug Administration (FDA), the company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. 21 May 2025
Pharmaceutical
The Dementia Discovery Fund (DDF) - managed by healthcare fund manager SV Health Investors - has announced the final closing of its second fund, DDF-2, with $269 million in commitments. 21 May 2025
Pharmaceutical
Earlier this month, the US Department of Health and Human Services (HHS) said it would require all future vaccines to undergo testing in placebo-controlled trials before being approved for use. 21 May 2025
Pharmaceutical
Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent. 21 May 2025
Pharmaceutical
Swiss reproductive and women’s health medicines specialist ReproNovo today announced the successful closing of a $65 million Series A financing round, which will be used to advance its pipeline of multiple Phase II programs. 21 May 2025
Pharmaceutical
North Carolina, USA-based vTv Therapeutics has announced that screening has been reinitiated in the company’s CATT1 Phase III trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D). 21 May 2025
Biotechnology
US biotechs Protagenic Therapeutics and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. 21 May 2025
Biotechnology
UK-based Juvenescence, a clinical stage AI-enabled biotech company, has secured a total of $76 million in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors. 21 May 2025
Pharmaceutical
UK-based PureTech Health delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. 21 May 2025
Pharmaceutical
US biotech Tourmaline Bio has reported topline data from a Phase II trial of its lead asset, pacibekitug, in people with chronic kidney disease (CKD) and elevated inflammation levels associated with cardiovascular risk. 21 May 2025
Pharmaceutical
US biotech company SparX Biopharmaceutical has signed a research agreement with Mitsubishi Tanabe Pharma America aimed at advancing a new antibody-drug conjugate (ADC) that targets a novel immune cell protein. 21 May 2025
Biotechnology
German antibody drug conjugate (ADC) specialist Tubulis announced that the first program from its 2023 licensing accord with pharma major Bristol Myers Squibb has entered clinical development, triggering a significant milestone in the ongoing collaboration to develop next generation antibody drug candidates (ADCs) for the treatment of cancer. 21 May 2025
Pharmaceutical
US healthcare giant Johnson & Johnson presented long-term findings from the 24-month open-label extension of the A DUE trial of Opsynvi (macitentan and tadalafil) in pulmonary arterial hypertension (PAH) during a late-breaking oral session at the American Thoracic Society (ATS) Conference. 21 May 2025
Biotechnology
South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running patent dispute concerning exports of its 13-valent pneumococcal conjugate vaccine, SKYPneumo (pneumococcal 13-valent conjugate vaccine). 21 May 2025
Biotechnology
A panel of experts convened by the US regulator has given a cautious nod to Johnson & Johnson’s Darzalex Faspro (daratumumab/hyaluronidase-fihj) for some multiple myeloma patients. 21 May 2025
Pharmaceutical
A week after US President Donald Trump signed an executive order to bring back the Most Favored Nation (MFN) idea he introduced at the end of his first term, the US Department of Health and Human Services (HHS announced it is proceeding with implementing the order on prescription drug pricing. 20 May 2025
Pharmaceutical
German drugmaker Grünenthal has named Maren Thurow as its new vice president and head of global communications, stepping into the role at a time of significant business expansion and leadership change. She succeeds Florian Dieckmann, who had led the company’s communications function since 2021. 20 May 2025
Pharmaceutical
Australia’s digital health sector is poised for steady expansion, with the market forecast to grow at a compound annual growth rate of around 8% through 2034, according to research from data and analytics group GlobalData. 20 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze